initi price target
im gon na make euroimmun offer refus
valuat alreadi inflect given impli upsid euroimmun
enter neutral share await capit
deploy growth acceler fear sub
core averag could curtail multipl sign emerg clearli
misjudg market patienc share ralli euroimmun
event correct share come post difficult print
obvious posit u/g turn page
growth set improv comp somewhat easi
howev would argu valuat alreadi inflect albeit rel p/
es remain reason furthermor acknowledg must
work euroimmun opportun notabl china ascertain
sustain double-digit growth rate busi enjoy
momentum tie seri key new product introduct
term core busi also await benefit key
product introduct could potenti off-set increasingli
challeng comp notabl food larg order said macro
back-drop remain favor prove tailwind
da would also note euroimmun deal rais leverag
profil notabl like make year debt pay-down
small tuck-in vs anyth sizeabl put togeth
take wait-and-se approach await either pull-back
valuat evid acceler prior becom
construct given dynam see risk reward balanc
thu initi share rate
thing watch trajectori da core rate euroimmun
growth post close birth rate us
debat portfolio reshuffl impact core growth
profil sizeabl lt omx opportun still exist
valuat price target base dcf methodolog
contempl wacc termin ebitda multipl
equat perpetu growth rate pt
translat ebitda vs average p/
 basi translat vs average
downsid risk potenti synchron global deceler
pmi post recent expans yield averag core growth rate
mute growth us birth rate could begin neg pressur
growth core pre/neo natal diagnost busi challeng
upsid risk recent restructur da favor fx
environ yield greater expect omx despit unfavor mix
shift new product momentum notabl intro vanadi acceler
core growth across portfolio yield rel price-to-earnings expans
one remain smid-cap diversifi tool player valuat
bias higher given potenti strateg option
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
initi pt
im gon na make euroimmun offer cant refus
last page report import disclosur regard stock report
tabl content
compani overview focus healthier world
debat portfolio reshuffl impact core growth profil
financi model major ep boost
point differenti vs st
iv valuat risk outsiz em exposur
 conclus initi acceler captur
waltham focus healthier world
diversifi tool player w/ big push dx market
global provid broad portfolio solut target
diagnost research environment industri
reorgan recent sizeabl euroimmun
push dx alreadi reflect ep valuat
rate valuat pt pt
ebitda vs average
price-to-earnings vs average
risk materi slowdown emerg market
china india challeng integr euroimmun
ceo friel led total transform busi
formerli evp cfo
set retir august
previous gm ge women
previous viacord
debat portfolio reshuffl impact core growth profil
management reorg portfolio w/ custom exposur mind
recent reorgan portfolio sold imag
busi varian medic mm
recent increas exposur high growth area
oper segment recast human health hh
 environment health eh diagnost
da rev includ previou segment
perten instrument food qa/qc
diagnost rev includ previou segment
portfolio trim busi dilut growth margin
start bear fruit w/ improv core
go forward recent likley add core
growth bias vs recent trend given increas bia em diagnost
driven partli mix shift lean mfg initi
reduc headcount invest
omx low-hang fruit sg expens
sg rev
 rev
momentum
measur pace
oncesourc grow msd w/ marque win
breadth servic offer led biggest win histori
past sever qs
recent biggest servic contract onesourc histori
competit peer
differenti among breadth servic includ
keep instrument run data management
momentum
build legaci
 innov
model summari point differenti vs street
swing factor accret euroimmun cadenc magnitud omx trajectori us birth
point differenti
revenu st core
acceler fx
 addit
acceler
ep st w/ spike
euroimmun
rel appeal
transform portfolio yield strong core growth ep momentum
million except per share data fy end decemb organ analyt solut organ organ gp less total analyt solut op less ep share inc net inc price-to-earnings prem disc januari
rel valu could upward bias growth acceler
absolut multipl appear elev notabl ebitda although rel metric appear favor
risk point balanc risk reward profil outsiz em exposur offer better growth also volatil
potenti synchron global deceler pmi post recent expans yield averag core growth rate
mute growth us birth rate could begin neg pressur growth core pre/neo natal diagnost busi
challeng integr tulip euroimmun heavi em exposur could materi alter core growth accret potenti
recent restructur da favor fx environ yield greater expect omx despit unfavor mix shift
new product momentum notabl intro vanadi reacceler core growth across portfolio yield rel price-to-earnings expans
one remain smid-cap diversifi tool player valuat bias higher given potenti strateg option
dcf valuat yield price
dcf deriv pt impli termin growth rate impli ebitda multipl
assumpt underli dcf valuat methodolog
year ebita margin assumpt
termin ebitda multipl
tax rate
wacc base beta risk free rate cost debt
assumpt impli termin growth rate
discount ebitda termin free flow enterpris total valu valu per perpetu growth valu enterpris enterpris valu januari
conclus initi pt return
ep inflect accur reflect absolut valuat await core confirm prior next move higher
enter neutral share await capit deploy growth acceler
fear sub core averag could curtail multipl sign emerg
clearli misjudg market patienc share ralli euroimmun event
correct share come post difficult print obv posit u/g
turn page growth set improv comp somewhat easi
howev would argu valuat alreadi inflect albeit rel p/e remain reason
furthermor acknowledg must work euroimmun opportun notabl
china ascertain sustain double-digit growth rate busi enjoy
term core busi also await benefit key product introduct
could potenti off-set increasingli challeng comp notabl food larg order
said macro back-drop remain favor prove tailwind da
would also note euroimmun deal rais leverag profil notabl
like make year debt pay-down small tuck-in vs anyth sizeabl
put togeth take wait-and-se approach await either
pull-back valuat evid acceler prior becom construct
given dynam see risk reward balanc thu initi share rate
thing watch trajectori da euroimmun growth birth rate us
pleas feel free reach question follow-up
medic suppli devic
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin januari et
analyst ross muken vijay kumar luke sergott primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research
